Shannon Connelly

Individualized treatments are key for older patients with breast cancer, expert Arti Hurria, M.D. said.

Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.

Leonard Gomella, M.D., recommends that healthcare providers familiarize themselves with how each novel biomarker should be used and then decide which one to use for a more individualized approach in clinical practice.

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.

Though now used for patients with grade 4 brain tumors, tumor treating fields are being tested for use in grade 3 tumors.

A recent study found that frequent, moderate exercise may reduce mortality and progression in patients with metastatic colorectal cancer.

Genetics can help determine a patient's risk of developing a brain tumor, as well as what treatments may work.

An early stage trial found that a new drug combination can reduce the rates of treatment-related diarrhea in patients with breast cancer.

Immunotherapy may be a promising option for patients with osteosarcoma, Nancy Gordon, M.D., says.

Recent findings turned more attention toward the metabolic pathways in neuro-oncology.

The FDA has approved AeroForm, a balloon-like wireless tissue expander, for patients who choose to have reconstructive surgery following a mastectomy or for those with underdeveloped breasts and soft tissue deformities.

In the future, entrectinib may play an increasing role in the treatment of brain tumors, as well as other cancers.

Immunotherapy's role for treating sarcoma is being cemented as more agents and targets are identified.

Robotic surgery is a promising option in the field of prostate cancer, leading to better outcomes and shorter hospital stays.

Rimas Lukas discusses the evolving field of glioblastoma multiforme (GBM) treatment.

Geoffrey Sklar, M.D. talks about the successes of immunotherapy agents like Opdivo, and where this research is moving in the field of bladder cancer.

While treatment advances have led to more survivors of medulloblastoma, the most common form of pediatric brain cancer, therapeutic approaches with fewer long-term effects are still needed.